Key Takeaways
- • NSV, a Singapore-based venture-building and investment firm specializing in biotechnology, announced the first close of its inaugural institutional fund at S$70 million, equivalent to $54.8 million, exceeding its initial target.
- • The fund's backers include government-linked entities Taiwan's National Development Fund and Singapore's EDBI.
- • The announcement came on a Monday in a difficult fundraising environment for venture capital, according to the primary source.
- • NSV says it is confident in delivering returns despite prevailing market risks.
Summary
NSV, a venture-building and investment firm based in Singapore with a focus on biotechnology, announced the first close of its inaugural institutional fund at 70 million Singapore dollars, equivalent to $54.8 million, according to Dow Jones. The close exceeded the firm's initial fundraising target.
The fund has attracted government-linked institutional backers, including Taiwan's National Development Fund and Singapore's EDBI. The participation of these entities signals institutional confidence in NSV's biotech strategy at a time when venture capital fundraising is described as challenging.
The article notes that raising venture capital is difficult under current conditions, and NSV's management expresses confidence that the fund can generate returns despite prevailing risks. The primary source does not disclose a final fund target, individual commitment sizes, or the timeline for a final close.
Additional coverage of the same announcement appeared in The Wall Street Journal under the headline "VC Firm NSV Raises Nearly $55 Million in First Close of Inaugural Biotech Fund."
The fund has attracted government-linked institutional backers, including Taiwan's National Development Fund and Singapore's EDBI. The participation of these entities signals institutional confidence in NSV's biotech strategy at a time when venture capital fundraising is described as challenging.
The article notes that raising venture capital is difficult under current conditions, and NSV's management expresses confidence that the fund can generate returns despite prevailing risks. The primary source does not disclose a final fund target, individual commitment sizes, or the timeline for a final close.
Additional coverage of the same announcement appeared in The Wall Street Journal under the headline "VC Firm NSV Raises Nearly $55 Million in First Close of Inaugural Biotech Fund."
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.